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The exudative form of Age-Related Macular
Degeneration (ARMD) is associated with a
particularly poor visual prognosis and accounts for
88% of ARMD sufferers who are registered blind.' In
this disease, characteristic changes occur in the
posterior pole of the eye within the confines of the
macula which is the region of the retina responsible
for central vision. When visual loss results from
progressive degeneration of the retinal pigment
epithelium and photoreceptors the condition is known
as dry macular degeneration. In a significant
proportion ofeyes there is invasion ofthe sub-pigment
epithelial and sub-retinal spaces by new blood vessels
originating from the choroid. The infiltrating vessels
are enmeshed in fibrous inflammatory tissue
constituting a choroidal neovascular membrane
(CNVM).2 The natural history of a CNVM is one of
rapid expansion with increasing leakage of fluid and
blood associated with progressive severe visual loss.
The neovascular channels within the membrane
eventually stop perfusing and involute with the
development of a fibrous disciform scar. The
morphogenesis of the scarring process destroys the
retinal pigment epithelium and the photoreceptors and
is incompatible with normal central visual function.
Laser photocoagulation has been used for many years
to ablate those choroidal neovascular membranes
which are located outside the foveal avascular zone.3
Laser photocoagulation of the foveal avascular zone
will of necessity destroy the foveal photoreceptors
resulting in complete loss of the central 5° of visual
field and an immediate fall in visual acuity. In 1991
the Macular Photocoagulation Study Group (MPS)
showed that well-defined sub-foveal membranes no
larger than 3.5 disc areas benefit from laser
photocoagulation.4 In this study, patients treated with
laser photocoagulation showed on average a 3.3 line
fall in acuity from baseline while controls showed a
3.7 line drop at 12 months; a difference of 0.4 lines.
With continuing follow up, at 18 months and at 24
months, treated patients had visual acuities which
were one line or two lines of vision better than that
which was found in the no treatment group.4 However
as already stated, treatment destroys the fovea and
there is an immediate marked fall in visual acuity (on
average a fall of 3 lines on the Snellen chart).5 It is
therefore questionable whether a long-term marginal
visual benefit at the cost of an immediate significant
deterioration in vision is worthwhile. Understandably
alternative treatment modalities are being sought.
It has been known for a long time that ionising
radiation can limit cell growth and division, with
rapidly dividing cells showing a greater degree of
susceptibility to the lethal effects of ionising
radiation.6 Ionising radiation has been used to limit
contraction and scar formation in surgical wounds for
over 40 years and the elegant studies of Grillo and
Potsaid were the first to shed light on the primary role
of fibroblasts in wound repair and their inhibition by
radiation.7 In ourlaboratories, studies carried outinthe
experimental animal have shown that low dose
ionising radiation applied focally at the site of an
ocular perforation causes a marked reduction in the
vascularity ofthe granulation tissue with an associated
decrease in the proliferation of scar tissue and traction
retinal detachment. Focal radiotherapy did not
adversely affect the adjacent healthy retina and
choroid as evidencedby histological examination.8 We
have also determined the radiosensitivity of retinal
microvascular endothelial cells in vitro and in vivo
and the results indicate that a single dose of radiation
in the region of500 cGy is sufficient to arrest division
in 99% ofirradiated endothelial cells. 9
In addition to the high degree of radiosensitivity of
vascular endothelial cells, the use of radiation has
other theoreticae advantages. Following laser,
recurrent neovascularisation has been identified as the
principal cause of continuing visual loss. It has been
suggested that, the inflammatory element of the
CNVM appears to be an important component in the
formation of the membranes, release of enzymatic
products and its remodelling.'0 Treatment of CNVM
by laser photocoagulation results in damage to tissue
which can evoke an inflammatory response with
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further recruitment of macrophages. These
inflammatory cells are potent inducers of
neovascularisation through the production of
cytokines and angiogenic growth factors."1 As
inflammatory cell recruitment is inhibited by low
doses ofionising rays, treatment ofthe CNVM by this
modality is unlikely to provoke recurrent
neovascularisation. Thus the studies carried out in our
laboratories have provided the theoretical basis for the
use of low-dose ionising radiation as a suitable
treatment modality in the management of sub-foveal
CNVM of ARMD. The next logical step was a phase
HI Clinical trial to determine whether low-dose
radiation to the macular region could influence the
natural course of age-related sub-foveal
neovascularisation. These phase 1/11 trials were
commenced in 1990 and the results of these studies
have been reported extensively in the scientific
literature.12-14
Overview ofresults
Fifty three patients with sub-foveal neovascularisation
on fluorescein angiography were identified for
inclusion into the study. The angiograms of all these
patients showed early leakage of dye seen as
hyperfluorescence which increased in intensity and
area and which involved the foveal avascular zone.
The patients were fully counselled on the nature of
their condition and treatment options available. From
January 1992 those patients who fitted the MPS
criteria for foveal ablation4 were offered this treatment
but all declined. Any patient with pre-existing ocular
disease (eg. glaucoma, high myopia, chronic
inflammatory orneoplastic disorders) was excluded as
were those with systemic disorders (diabetes,
uncontrolled hypertension) or a known life-
threatening disease at enrolment into the study.
Informed consent to participate in the radiotherapy
study was obtained in all treated cases. Those patients
who declined radiotherapy were followed up as a non-
randomised comparison group (A total of 41 eyes
received radiotherapy and 13 eyes of 12 patients were
followed up as controls).
In the initial stages ofthe study (first 19 patients) two
treatment regimes were used with patients receiving
either lOGy (2Gyx5 fractions) or l5Gy (3Gyx5
fractions).12 The analysis of the initial results showed
stabilisation of central visual function in treated
patients which was accompanied by regression of the
neovascular membrane which was documented
angiographically. By contrast central vision in the
comparison group deteriorated significantly and the
neovascular membrane was seen to expand. The long-
term follow up data on 41 treated and 13 controls for
periods up to 60 months confimed that radiotherapy
appeared to induce regression of CNVM which was
associated with maintained visual acuity (Table 1). In
those patients who received IOGy, the rate of
regression of the neovascular membrane was slower
than that observed in those who received 15Gy
although final visual acuity was similar between
groups. The lack of statistical significance in visual
outcomebetween these two groups may havebeen due
to the small size of the pilot study or the absence of
any real difference between the two doses of
radiotherapy.
3Gy fractions areknownto be associated with ahigher
risk ofoptic neuropathy hence a new treatment regime
was instituted consisting of 12Gy delivered as 2Gy
fractions x 6. In order to allow for the radiobiological
effectiveness of these fractionation schedules the
nominal standard dose (NSD) which is expressed in
rets was calculated for each treatment regime. In a
seminal piece ofworkHarris andLevenel5 have shown
that there was a significant increase in the risk of
visual loss not only with fraction sizes exceeding 2 Gy
but also when the NSD exceeded 1500rets. In practice
the majority of radiotherapists do not prescribe in
fraction sizes in excess of 2Gy particularly when the
field of radiotherapy includes the brain and the eye.
These are important considerations as ARMD is a
non-life-threatening condition and since central vision
is already poor in ARMD sufferers, it would be
questionable clinical practice to compromise optic
nerve function by any therapeutic intervention. In this
context it should be noted that at least one investigator
has reported sight-threatening retinopathy in a patient
with dysthyroid ophthalmopathy treated with external
beam radiation at a total dose of 2OGy given in 10
fractions over periods of 10 to 14 days.'6 Our
calculations based on the information provided in this
paper show that the NSD in these patients was in the
region of 1120 to 1160 rets and thus we feel it prudent
to restrict the dose and fraction size to ensure a ret
value below 1000. In our study the NSD which is
expressed in rets did not exceed, 1000 rets in the 10 or
12Gy group and 1200 rets in the l5Gy group. On the
basis ofour clinical impression we are now electing to
treat all subsequent patients with 12Gy each as the
NSD is kept to below 1000 rets, giving us a wider
margin of safety than a dose of 15Gy.
Throughout the duration of the study, our patients
were monitored for any possible adverse side effects
which could be attributed to radiotherapy. Transient
conjunctival irritation was reported by one patient
with resolution within three weeks from radiotherapy
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TABLE 1
Summary ofPublished Phase lIIl studies
Group Radiation Dose Fraction NSD No. Cont Reference Results
Treated
Chakravarthy 6 MV P 10 5 x 2 571 19 7 BJO Stabilisation of VA
et al 1993;77:265- in 63% at 12 months
273
15 5x3 857
Bergink et al 16MVP 8 Ix8 900 17 none Graefes. Arch Stabilisation ofVA
1994; 232: 591 with doses in excess




Bergink et al 16 MV P 8 lx 8 900 40 none Doc Ophthal Stabilisation ofVA
1995;90: 67-74 with doses in excess




Finger et al 6 MV 14.4 8 x 1.2 695 75 none Ophthalmol Stabilisation ofVA
1996; 103: 878 in 48% at 9 months
lOx 1.44 642 889
Berson et al 6 MVP 14 8 x 1 75 G86 52 none Int. J Radiat Stabilisation ofVA
Oncol. Biol, in 79% at 7 months
15 1 x 1.88 735 1996;36:861-
865
Freire et al Not stated 14.4 8 x 1.8 685 39 none Int. J. Radiat Stabilisation ofVA
Oncol. Biol, in 92% at 3 months
1996;36:857
Valmaggia et 6 MeV E 5 4 x 1.25 409 46 none Klin. Stabilisation ofVA
al Monats 1996; with doses in excess
8 4 x 2 493 208:315-317 of8Gy in 72% at
6 months
Hartetal 6MVP 10 5x2 571 41 13 BJO StabilisationofVA
1996; 80:1046- in 65% at 48 months
15 5x3 857 1050
andthereafterthis patient has remained asymptomatic.
Another patient suffered transient alopecia areata
involving an area 2cmdiameter at the beam exitpoint.
Both these patients received l5Gy. Significant
progression of cortical and posterior subcapsular lens
opacities with accompanying loss of acuity was
observed in the treated eyes of two patients (both had
received l5Gy) after 36 months post-treatment.
Cataract extraction and intraocular lens insertion has
been carried out in both these patients. Post-surgery,
vision returned to the level measured priorto the onset
of lens opacities. Radiation induced retinal
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vasculopathy (microvascular abnormalities, leakage
and cotton wool spots) or optic neuropathy (disc
pallor) were not observed clinically. Angiograms were
scrutinised for evidence of retinal microvascular
abnormalities and none was found.
Discussion and Summary
Various novel treatments have been proposed in recent
years for the management of CNVM untreatable by
laser. Interferon a 2a which is a potent inhibitor of
vascularendothelial cell proliferation and migration in
culture has been used systemically in the treatment of
sub-foveal CNVM.17 To date this treatment option has
not proved significantly effective and it is also
associated with severe secondary effects which may
be local or systemic. Other experimental therapies
involve the use of thalidomide, retinoids, and
TABLE 2
Distribution ofVisualAcuity in Treated Eyes
Between 0 and 48 monthspostRadiotherapy
0 3 6 12 18 24 36 48
LogMar n=41 n=41 n=41 n=41 n=30 n=29 n=25 n=9
(Snellen)
0.0 0.6 27% 29% 39% 26% 23% 21% 20% 45%
(6/6 - 6/24)
0.78- 1.1 49% 46% 46% 42% 47% 38% 56% 33%
(6136 -5/60)
1.2-1.78 24% 25% 15% 32% 36% 41% 24% 22%
(4/60 -1/60)
Distribution ofVisualAcuity in Control Eyes
Between 0 and 48 monthspostRadiotherapy
0 3 6 12 18 24 36 48
LogMar n=13 n=13 n=13 n=13 n=12 n=10 n=8 n=4
(Snellen)
0.0- 0.6 47% 31% 31% 8% 0% 0% 0% 0%
(6/6 6/24)
0.78 - 1.1 38% 54% 31% 46% 58% 40% 38% 50%
(6/36 -5/60)
1 3 -1.78 15% 15% 38% 46% 42% 60% 62% 50%
(4/60 -1/60)
amiloride'9 all of which are known to possess
antiangiogenic properties. The results of such
treatments are as yet unavailable. Surgical excision of
CNVM has been attempted20 but the outcome is
significantly better in younger patients with presumed
ocular histoplasmosis rather than ARMD.21
Transposition of the retina has also been considered,
however these are all highly invasive procedures and
it is doubtful whether central visual function can be
preserved or improved by such drastic surgery.
Radiotherapy is attractive as it can be delivered to a
precise location, itis non-invasive andhas no systemic
side effects at low doses. Since the publication of our
original studies on radiotherapy in ARMD there has
been increasing interest in this treatment modality
.External beamradiation as employed by other centres
in the management of CNVM has included dose
regimes ranging from 8Gy to 24Gy
(Table 2). The fractionation
schedules varied considerably and
fraction sizes as large as 8Gy have
been used.22-23 Where cyclotron
facilities were available proton beam
irradiation has been used which with
its highly collimated beam and
sharply definedBragg Peakeffecthas
theoretical advantages in the
treatment of CNVM.24 Alternatively
brachytherapy rather than teletherapy
has also been tried with some
investigators using Pd 103 or Sr 90
plaques (beta emitters) designed to
deliver doses between 12.5 and l5Gy
to the region of the CNVM.25-26 Most
of these recent reports suggest a
positive treatment effect in the short
term. Although no adverse effects
have been reported in any of these
studies it should be noted that the
follow-up times have in general been
less than one year.
In summary the basis for the use of
ionising radiation to inhibit growth of
CNVM of ARMD has been
underpinned by many years of
information gleaned from basic
laboratory studies. These studies are
now quoted extensively in the
literature by researchers worldwide
as the rationale for commencing
clinical trials of this treatment
modality in ARMD. Our preliminary
phase I/II trials are also enshrined in
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the literature as they were the first to explore the
potential of radiotherapy in the management of
subfoveal CNVM. A number of multicentre
randomised controlled studies are now progressing
and a more definitive answer should be available very
soon.
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